Fig. 6

Evaluation of cancer therapy agents in the high-risk and low-risk patient groups. A The half maximal inhibitory concentration (IC50) values for each of 6 anticancer drugs (etoposide, imatinib, methotrexate, rapamycin, vinorelbine, and vorinostat) were compared between the high-risk group and the low-risk group, and the results are displayed in box plots. Each dot represents the estimated IC50 value of the corresponding drug in the LUSC sample. The higher the IC50 is, the less sensitive the LUSC sample is to the drug. B The scores of 16 immune cells. C The scores of 13 immune-related functions. DCs dendritic cells, iDCs immature DCs, pDCs plasmacytoid dendritic cells, TIL tumour-infiltrating lymphocyte, CCR cytokine–cytokine receptor, APC antigen-presenting cells. Adjusted P values are shown as follows: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001